drugset / Trial / NCT04419181
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer.
Timeline
- Start
- 2025-08-11
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
Outcome
Outcome not reported
Stopped: “Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials answering similar questions are expected to result in the next few years.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | — |